VistaGen Publishes Preclinical Data Supporting the Therapeutic Potential of AV-101 for Parkinson's Disease
AV-101 is a first-in-class prodrug that regulates critical glutamate signaling pathways in the brain, including those associated with the stimulation of neurons that produce dopamine. In the reported studies, animal models were used to measure the activity of dopaminergic (DA) neurons in the brain following the systemic administration of AV-101 (4-chlorokynurenine), which is converted in the brain into 7-chlorokynurenic acid, one of the most potent and selective regulators of the glycine-site of the NMDA receptor.
Treatment with AV-101 was found to increase the "firing rate" and "burst firing" activity of DA neurons by 27% and 61%, respectively. These are two key indicators of DA neuron function that are associated with the large release of dopamine that is critical to many important neuronal signaling events in the brain. Reduced production of dopamine is characteristic of Parkinson's disease, and is a major cause of the symptoms of the disease.
"Besides observing that AV-101 can stimulate the activity of neurons that produce dopamine, preliminary data suggest that AV-101 also may activate additional, quiescent DA neurons. We have not seen this type of dual activity in any other drug," said H. Ralph Snodgrass, Ph.D., VistaGen's President and CEO. "We are on track to submit an IND to the FDA in the first quarter of 2008 for clinical development of AV-101 for treatment of neuropathic pain and epilepsy. With the publication of these latest study results, we hope to extend our clinical studies to include Parkinson's disease."
Close to four million persons worldwide currently suffer from Parkinson's disease with an estimated $2 billion spent on drug therapy annually.
VistaGen Therapeutics, Inc. is an emerging biopharmaceutical technology leader applying patented embryonic stem cell technologies for predictive toxicology screening and to discover, develop and commercialize new drug and protein therapies for diabetes and neurological disorders, including neuropathic pain, Parkinson's disease and epilepsy. Founded in California in 1998, VistaGen discovers and develops drugs for its own pipeline through internal programs and collaborations with leading research organizations worldwide. VistaGen also leverages its proprietary embryonic stem cell technology platform through strategic collaborations with leading pharmaceutical companies worldwide. More information at www.vistagen.com
(1)Citation: Linderholm, et al., Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis, J. Neuropharm (2007), 10.1016/j.neuropharm.2007.09.003
Contact
Media
Russell Communications Group
Christine Thomas, 310-559-4955 x103
christinethomas@ruscom.com
or
Investors
Stern Investor Relations, Inc.
Lilian Stern, 212-362-1200
lilian@sternir.com
Posted: November 2007
